1006037-10-0

Basic information

• Product Name: Benzoic acid, 4-(1-isocyanatocyclopropyl)-, Methyl ester
• Synonyms: Benzoic acid, 4-(1-isocyanatocyclopropyl)-, Methyl ester;methyl 4-(1-isocyanatocyclopropyl)benzoate;LOHIMCYSVRCTTD-UHFFFAOYSA-N
• CAS NO: 1006037-10-0
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.22064
• Mol File: 1006037-10-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 4-(1-isocyanatocyclopropyl)-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(1-isocyanatocyclopropyl)-, Methyl ester(1006037-10-0)
• EPA Substance Registry System: Benzoic acid, 4-(1-isocyanatocyclopropyl)-, Methyl ester(1006037-10-0)

Safety Data

• Hazardous Substances Data: 1006037-10-0(Hazardous Substances Data)

Upstream product

• 75-44-5 phosgene 
• 1006037-03-1 4-(1-aminocyclopropyl)-benzoic acid methyl ester 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 1006037-11-1 methyl 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoate 

Relevant articles and documents

HETEROBICYCLIC COMPOUNDS AS EP4 ANTAGONISTS

The present invention relates to novel EP4 receptor antagonist compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, which can be useful for treating cancer or inflammatory diseases.

Scalable synthesis of a prostaglandin EP4 receptor antagonist

The evolution of scalable, economically viable synthetic approaches to the potent and selective prostaglandin EP4 antagonist 1 is presented. The chromatography-free synthesis of multikilogram quantities of 1 using a seven-step sequence (six in the longest

PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVE

The invention encompasses a process for making a thiophene carboxamide derivative, which is an EP4 antagonist useful for treating pain and inflammation.

THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS

The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoi